Cutaneous Rosai-Dorfman disease of the face with a leonine appearance: successful response to dapsone

Cutaneous Rosai-Dorfman Disease: A Treatment Challenge

“…Skin lesions in RDD manifest as erythematous nodules or plaques with a yellowish or violaceous hue, isolated or confluent, predominantly located on the head and neck and rarely on the trunk or the limbs and possibly tender on palpation [4]. The presentation of cutaneous RDD can imitate eruptive xanthoma, acneiform eruptions, sarcoma Kaposi, cutaneous lymphoma, disseminated tuberculosis and Langerhans cell histiocytosis [5,6,[9][10][11].…”

“…Topical and intralesional corticosteroids and topical imiquimod have been used to treat cutaneous RDD, with the effects varying from mild to total improvement [ 4 , 6 ]. For the treatment of refractory or extensive disease, there is some evidence of thalidomide [ 6 ], dapsone [ 9 ], imatynib [ 5 ] and low-dose weekly MTX as monotherapy or combined with steroids being efficacious [ 15 , 16 ]. A successful, total remission of cutaneous RDD after 11 months of treatment with 15 mg of MTX per week and triamcinolone injections prompted the introduction of this treatment [ 16 ].…”

Rosai‐Dorfman disease successfully treated with thalidomide: A case report

“…For the treatment of RDD, a combination of observation, surgical excision, corticosteroids, chemotherapy, immunomodulatory therapy, and radiotherapy can be approached according to the grade and degree of disease progression (Gaul & Chang, 2019;Lee, Kim, Oh, & Kim, 2018). One of the main immunomodulatory drugs is thalidomide that has been applied successfully for treatment and remission of RDD.…”